To print: Select File and then Print from your browser's menu

Title: Medarex Announces FDA Fast Track Designations for Ipilimumab for the Treatment of Metastatic Melanoma

"Medarex Announces FDA Fast Track Designations for Ipilimumab for the Treatment of Metastatic Melanoma"

Fast Track Designations for First-Line Use in Combination With Chemotherapy and Second-Line Use as Monotherapy PRINCETON, NJ -- December 7, 2006 -- Medarex, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ipilimumab (also known as MDX- 010) used in combination with chemotherapy (dacarbazine) in previously untreated (first-line) metastatic melanoma patients. The FDA also has granted Fast Track designation for ipilimumab used as a monotherapy in previously treated (second-line) metastatic melanoma patients. Under the FDA Modernization Act of 1997, designation as a Fast Track product for a new drug or biological product means that the FDA has determined that the drug or biologic is intended for the treatment of a serious or life- threatening condition and demonstrates the potential to address unmet medical needs for such a condition, and that the FDA will facilitate the clinical development and expedite the review of a Biologics License Application for the product. "We are pleased with the Fast Track designations as we continue to work with our partner Bristol-Myers Squibb to advance the development of ipilimumab, and we believe that ipilimumab has the potential to play an important role in the fight against cancer," said Irwin Lerner, Chairman of the Board of Directors and Interim President and CEO of Medarex. About ipilimumab Ipilimumab is an investigational fully human antibody against human CTLA- 4, a molecule on T cells that is believed to be responsible for suppressing the immune response. Medarex and Bristol-Myers Squibb are investigating the potential of ipilimumab to enable the immune systems of cancer patients to help suppress or eradicate cancer tumors. Ipilimumab is currently under investigation in several registrational clinical trials under Special Protocol Assessment agreements with the FDA for the treatment of metastatic melanoma -- as a first-line treatment in combination with dacarbazine, as a second-line monotherapy (enrollment expected to be completed this year) and as a second- line treatment in combination with MDX-1379 (a melanoma peptide vaccine). The combination with MDX-1379 was previously granted Fast Track designation. Ipilimumab is also being evaluated in multiple Phase II clinical trials to investigate the product's potential activity in other tumor types, as well as in combination studies with chemotherapy, immunotherapy and vaccines. Further information regarding Medarex's and Bristol-Myers Squibb's ipilimumab program can be found in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC). SOURCE: Medarex, Inc.

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.